All In Biotech

BLA 761044 · Janssen Biotech

Stelara

Ustekinumab · Injection · Interleukin-12 Antagonist; Interleukin-23 Antagonist

Orphan

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Sep 23, 2016

Approved uses

4

Original approval plus efficacy supplements

Registered trials

164

71 Phase 3, 28 recruiting

FAERS reports

103,163

61,436 serious, 6,203 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 16, 2026.

Ustekinumab is a human interleukin-12 and -23 antagonist indicated for the treatment of: Moderate to severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy. ( 1.1 ) Active psoriatic arthritis in adults and pediatric patients 6 years of age and older. ( 1.2 ) Moderately to severely active Crohn's disease in adults and pediatric patients 2 years of age and older. ( 1.3 ) Moderately to severely active ulcerative colitis in adults and pediatric patients 2 years of age and older. ( 1.4 ) 1.1 Plaque Psoriasis (PsO) Ustekinumab is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2 Psoriatic Arthritis (PsA) Ustekinumab is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3 Crohn's Disease (CD) Ustekinumab is indicated for the treatment of adults and pediatric patients 2 years of age and older with moderately to severely active Crohn's disease. 1.4 Ulcerative Colitis (UC) Ustekinumab is indicated for the treatment of adults and pediatric patients 2 years of age and older with moderately to severely active ulcerative colitis.

Mechanism: Ustekinumab is a human IgG1қ monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. In in vitro models, ustekinumab was shown to disrupt IL-12 and IL-23 mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12Rβ1. The cytokines IL-12 and IL-23 have been...

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • STELARA · USTEKINUMAB 130MG/26ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ustekinumab" as an intervention, any sponsor and status, largest first.

All 164 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective14,942
  • off label use12,880
  • product dose omission issue10,242
  • fatigue6,966
  • psoriasis6,617
  • pain6,322
  • crohn^s disease5,993
  • arthralgia5,902
  • rash5,714
  • product use issue5,463
  • headache5,377
  • condition aggravated5,316

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200934
2010339
2011836
20121,456
20131,849
20141,704
20155,305
20164,517
20176,660
20188,727
201910,236
202013,325
20217,743
20229,895
202310,036
20249,237
20257,214
20264,050

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Stelara* (Ustekinumab)

2024 spending

$3.38B

Beneficiaries

24,754

132,865 claims

Per beneficiary

$136,463

$26,534.27 per unit

View as table
YearSpending
2020$1,106,356,248
2021$1,567,482,458
2022$2,339,082,716
2023$2,987,778,600
2024$3,378,017,374

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 577 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.